Joint IRB to review multicenter clinical studies

Published: 2007-05-04 06:58:00

Updated: 2007-05-04 06:58:00

The Korea Food and Drug Administration said on May 1 that multicenter clinical trials will be reviewed by a joint Institutional Review Board (IRB) in a bid to ensure more speedy clinical tests for home-grown drugs.

The purpose of an IRB review is to assure, both in advance and by periodic revi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK